GlassScriptPhysician profile
Deyi Zheng
NPI 1497871438
$4,760.65
in general payments reported to CMS, 2019-2025
37 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $747 · 2021: $411 · 2022: $781 · 2023: $697 · 2024: $1,017 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $895.40 | 2019-2025 | |
| Lilly USA, LLC | $824.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $330.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.98 | 2020-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $254.49 | 2019-2021 | |
| Allergan, INC. | $228.49 | 2019-2020 | |
| Abbott Laboratories | $207.92 | 2024-2025 | Diamondback Peripheral, Proclaim |
| Janssen Pharmaceuticals, INC | $177.89 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $142.37 | 2022-2023 | Verquvo, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $126.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $101.88 | 2021 | |
| Abbvie INC. | $94.27 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $93.42 | 2020-2024 | Shingrix, Arexvy |
| Nevro Corp. | $86.67 | 2022-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $68.77 | 2022-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deyi Zheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.